2011
DOI: 10.1002/emmm.201100122
|View full text |Cite
|
Sign up to set email alerts
|

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium

Abstract: The telomeric amplicon at 8p12 is common in oestrogen receptor-positive (ER+) breast cancers. Array-CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical on… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
148
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 120 publications
(157 citation statements)
references
References 35 publications
9
148
0
Order By: Relevance
“…We also saw amplification in 69.23% of patients' plasma samples in four markers from the 10-kb interval that spans ZNF703, although amplification was also seen in 50.00% of plasmas from the healthy controls and 32.30% of patients' normal leukocytes. This gene has recently been shown to be a novel oncogene in Luminal B breast cancer (Holland et al 2011). Overall, the pattern of genomic alteration seen, with focal highlevel DNA amplification clustered at several chromosome arms, resembles the ''amplifier'' or ''firestorm'' type of DNA CN alterations, detected in previous genomic profiling of breast tumors (Kwei et al 2010).…”
Section: Cfdna Of Breast Cancer Patients Infers Dormancymentioning
confidence: 58%
“…We also saw amplification in 69.23% of patients' plasma samples in four markers from the 10-kb interval that spans ZNF703, although amplification was also seen in 50.00% of plasmas from the healthy controls and 32.30% of patients' normal leukocytes. This gene has recently been shown to be a novel oncogene in Luminal B breast cancer (Holland et al 2011). Overall, the pattern of genomic alteration seen, with focal highlevel DNA amplification clustered at several chromosome arms, resembles the ''amplifier'' or ''firestorm'' type of DNA CN alterations, detected in previous genomic profiling of breast tumors (Kwei et al 2010).…”
Section: Cfdna Of Breast Cancer Patients Infers Dormancymentioning
confidence: 58%
“…A number of the changes of FLHCC have the hallmarks of some forms of breast cancer (SI Appendix, Table S13). Some of transcripts that are considered oncogenic for breast cancers are also increased in FLHCC including AURKA CYP19A1 (67), the breast cancer anti-estrogen resistance 1 (BCAR1), and ZNF 703, a luminal B breast cancer oncogene (68), as well as members of the EGF receptor pathway, including EGFR, ErbB2, and their ligands NRG2, EREG, AREG, and NGF.…”
Section: Discussionmentioning
confidence: 99%
“…ZNF703 is a zinc finger transcription factor belongs to NET/NLZ family and contributes to the development and progression of various cancer, including NSCLC, breast cancer, gastric cancer (GC), and colorectal cancer (CRC). [40][41][42] Moreover, ZNF703 is involved in the activation of the Akt/mammalian target of rapamycin (mTOR) signaling pathway in breast cancer cell lines. 43 Therefore, Shi et al 11 detected the potential roles of ZNF703 in breast cancer cell lines and discovered that ZNF703 is augmented in breast cancer tissues and cell lines.…”
Section: Breast Cancermentioning
confidence: 99%